| Literature DB >> 35836934 |
Arun Chandra Manivannan1, Arunkumar Malaisamy2, Murugesh Eswaran3, Arun Meyyazhagan4, Vijaya Anand Arumugam5, Kannan R R Rengasamy6, Balamuralikrishnan Balasubramanian7, Wen-Chao Liu8.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus can cause a sudden respiratory disease spreading with a high mortality rate arising with unknown mechanisms. Still, there is no proper treatment available to overcome the disease, which urges the research community and pharmaceutical industries to screen a novel therapeutic intervention to combat the current pandemic. This current study exploits the natural phytochemicals obtained from clove, a traditional natural therapeutic that comprises important bioactive compounds used for targeting the main protease of SARS-CoV-2. As a result, inhibition of viral replication effectively procures by targeting the main protease, which is responsible for the viral replication inside the host. Pharmacokinetic studies were evaluated for the property of drug likeliness. A total of 53 bioactives were subjected to the study, and four among them, namely, eugenie, syzyginin B, eugenol, and casuarictin, showed potential binding properties against the target SARS-CoV-2 main protease. The resultant best bioactive was compared with the commercially available standard drugs. Furthermore, validation of respective compounds with a comprehensive molecular dynamics simulation was performed using Schrödinger software. To further validate the bioactive phytochemicals and delimit the screening process of potential drugs against coronavirus disease 2019, in vitro and in vivo clinical studies are needed to prove their efficacy.Entities:
Keywords: SARS-CoV-2; casuarictin; clove; main protease; phytochemicals
Year: 2022 PMID: 35836934 PMCID: PMC9273859 DOI: 10.3389/fmolb.2022.918101
Source DB: PubMed Journal: Front Mol Biosci ISSN: 2296-889X
FIGURE 1Graphical representation of top-ranked phytochemicals docked against the MPro unit of binding energy [∆G (−kcal/mol)].
Interaction between the amino acid residue of COVID -19 main protease and ligands at receptor sites.
| Ligands | Interacting Species and Bond Distance | ||
|---|---|---|---|
| Hydrogen Binding Interaction | Hydrophobic Interaction | Electrostatic Interaction | |
| Casuarictin, (CHEMBL1076705) | Thr199 (3.02), Asp197 (3.79), Arg131 (2.76), Lys137 (2.46), and Leu287 (3.53) | Leu287 (5.30), Leu272 (5.12), and Tyr239 (5.20) | — |
| Eugeniin | Ala285 (3.38), Leu287 (3.08), Lys236 (2.67), Asn238(2.57), Lys137 (2.85), Thr199 (3.07), and Arg131 (2.98) | Tyr237 (5.04) | Lys236 (3.98) |
| Syzyginin B | Lys137 (2.70), Arg131 (2.10), Asp289(281), Glu228 (3.38), Leu287 (3.33), and Thr199 (2.53) | Leu287 (4.89) | — |
| Eugenol | Phe294(3.79), Gln110 (2.29), and Ala129 (1.96) | - | — |
| Protopine | Leu271 (3.46) and Leu287 (2.51) | Leu287 (4.66) | — |
| Eugenyl Benzoate | Cys145 (3.24), His163 (3.55), Ser144 (3.13), and Phe140(3.62) | Met165 (5.09), Cys145 (4.53), and His163 (4.68) | — |
| 1-Methyloctyl Acetate | Cys145 (2.34), His163 (2.61, Phe140(3.35), and His163 (2.14) | — | Glu166 (4.78) |
| Eugenol Acetate | Gln110 (2.18), Asn151(2.25), and Ser158(3.55) | — | — |
FIGURE 2Molecular docking interaction of target proteins with clove’s phytochemicals of (A) casuarictin, (B) eugeniin, (C) protopine, (D) syzyginin B, and (E) eugenol.
FIGURE 3Ligand occupancy in an active site of a target protein complex molecule of (A) syringin, (B) eugeniin, (C) syzyginin, (B,D) eugenol acetate, (E) protopine, and (F) 1-methyloctyl acetate.
FIGURE 4Off-target prediction of selected compounds including beta secretase, squalene mono-oxygenase, thrombin, and coagulation factor.
FIGURE 5RMSD value of the complex molecule of the main protease with (A) syzyginin B, (B) eugeniin, and (C) eugenol.
ADME/T properties of various compounds that exhibited a high binding efficiency.
| Title (and Range) | Syzyginin (ZINC230067171) | Syzyginin B | Eugeniin | Casuarictin | Protopine | Eugenol |
|---|---|---|---|---|---|---|
| #amine (0–1) | 0 | 0 | 0 | 0 | 1 | 0 |
| #amidine (0) | 0 | 0 | 0 | 0 | 0 | 0 |
| #acid (0–1) | 0 | 0 | 0 | 0 | 0 | 0 |
| #amide (0–1) | 0 | 0 | 0 | 0 | 0 | 0 |
| CNS (-2 inactive and +2 active) | -2 | -2 | -2 | -2 | 2 | 0 |
| mol MW (130.0–725.0) | 756.54 | 756.54 | 938.672 | 936.657 | 353.374 | 164.204 |
| Dipole (1.0–12.5) | 3.342 | 7.316 | 4.159 | 10.409 | 2.299 | 1.859 |
| SASA (300.0–1,000.0) | 915.82 | 924.397 | 1,186.696 | 1,133.803 | 508.221 | 401.412 |
| FOSA (0.0–750.0) | 105.614 | 97.55 | 66.353 | 76.301 | 310.695 | 204.373 |
| FISA (7.0–330.0) | 612.263 | 621.364 | 835.169 | 810.688 | 26.505 | 51.309 |
| PISA (0.0–450.0) | 197.944 | 205.484 | 285.174 | 246.814 | 171.021 | 145.731 |
| WPSA (0.0–175.0) | 0 | 0 | 0 | 0 | 0 | 0 |
| Volume (500.0–2000.0) | 1786.437 | 1800.373 | 2,304.514 | 2,217.198 | 973.528 | 641.616 |
| donorHB (0.0–6.0) | 12 | 12 | 15 | 14 | 0 | 1 |
| accptHB (2.0–20.0) | 19.6 | 19.6 | 22.95 | 21.95 | 7 | 1.5 |
| dip^2/V (0.0–0.13) | 0.006252 | 0.029726 | 0.007507 | 0.048864 | 0.005431 | 0.005386 |
| ACxDN^.5/SA (0.0–0.05) | 0.074137 | 0.073449 | 0.074901 | 0.072437 | 0 | 0.003737 |
| Glob (0.75–0.95) | 0.777,464 | 0.774,251 | 0.711,015 | 0.725,266 | 0.934,713 | 0.89624 |
| QPpolrz (13.0–70.0) | 58.24 | 58.87 | 75.312 | 74.02 | 34.44 | 18.347 |
| QPlogPC16 (4.0–18.0) | 23.298 | 23.568 | 31.713 | 29.985 | 9.054 | 5.793 |
| QPlogPo/w (-2.0–6.5) | -2.911 | -2.905 | -3.469 | -3.237 | 1.727 | 2.666 |
| QPlogS (-6.5–0.5) | -3.622 | -3.716 | -4.733 | -5.061 | -0.963 | -2.35 |
| QPPCaco (<25 poor, >500 great) | 0.015 | 0.013 | 0 | 0 | 1,385.006 | 3,231.023 |
| QPlogBB (-3.0–1.2) | -7.033 | -7.191 | -11.716 | -10.736 | 0.76 | -0.103 |
| QPPMDCK (<25 poor, >500 great) | 0.003 | 0.003 | 0 | 0 | 778.255 | 1757.464 |
| QPlogKp (-8.0 to −1.0) | -10.762 | -10.903 | -13.891 | -13.959 | -3.468 | -1.568 |
| IP(eV) (7.9–10.5) | 8.542 | 8.383 | 9.017 | 8.897 | 8.923 | 8.729 |
| EA (eV) (-0.9–1.7) | 0.881 | 0.658 | 0.634 | 0.737 | 0.406 | -0.232 |
| QPlogKhsa (-1.5–1.5) | -1.035 | -1.025 | -1.246 | -0.984 | -0.428 | -0.113 |
| Human Oral Absorption | 1 | 1 | 1 | 1 | 3 | 3 |
| Percent Human Oral Absorption (>80% is high, <25% is poor) | 0 | 0 | 0 | 0 | 93.285 | 100 |
| RuleOfFive (maximum is 4) | 3 | 3 | 3 | 3 | 0 | 0 |
| RuleOfThree (maximum is 3) | 2 | 2 | 2 | 2 | 0 | 0 |